Australian Pharmaceuticals & Biotech Most Popular Stocks

CSL

Market Cap: AU$96.1b

Engages in the research, development, manufacture, market, and distribution of biopharmaceutical products and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

Telix Pharmaceuticals

Market Cap: AU$5.1b

A commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.

Mesoblast

Market Cap: AU$3.1b

Engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland.

Neuren Pharmaceuticals

Market Cap: AU$2.5b

A biopharmaceutical company, develops drugs for the treatment of neurological disorders.

Clarity Pharmaceuticals

Market Cap: AU$1.4b

A clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States.

Opthea

Market Cap: AU$738.8m

A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States.

PYC Therapeutics

Market Cap: AU$621.2m

A drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia.

Clinuvel Pharmaceuticals

Market Cap: AU$601.5m

A biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally.

Race Oncology

Market Cap: AU$540.5m

A clinical stage biopharmaceutical company, focuses on addressing the unmet needs of cancer patients for damaging treatments in Australia.

Mayne Pharma Group

Market Cap: AU$460.7m

A specialty pharmaceutical company, focuses on the commercialization of women’s health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally.

Immutep

Market Cap: AU$381.6m

A biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia.

Orthocell

Market Cap: AU$353.4m

A regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally.

Dimerix

Market Cap: AU$321.1m

A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia.

Botanix Pharmaceuticals

Market Cap: AU$304.0m

Operates as a commercial dermatology company in Australia and the United States.

Aroa Biosurgery

Market Cap: AU$234.6m

Develops, manufactures, and sells medical devices for wound and soft tissue repair using extracellular matrix (ECM) technology in the United States and internationally.

Tetratherix

Market Cap: AU$207.4m

Engages in biomaterial and regenerative medicine business in Australia and internationally.

Paradigm Biopharmaceuticals

Market Cap: AU$138.0m

Engages in the research and development of therapeutic products for human use in Australia.

Vita Life Sciences

Market Cap: AU$135.7m

A healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China.

LTR Pharma

Market Cap: AU$130.3m

A clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia.

Recce Pharmaceuticals

Market Cap: AU$120.0m

Recce Pharmaceuticals Ltd, discovers, develops, and commercializes synthetic anti–infectives in Australia, the United Kingdom, and the United States.

Arovella Therapeutics

Market Cap: AU$116.1m

A biotechnology company, focuses on the development of therapies for the treatment of cancer in Australia and internationally.

Starpharma Holdings

Market Cap: AU$112.9m

A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.

EZZ Life Science Holdings

Market Cap: AU$112.7m

Engages in formulation, production, marketing, and sale of the health and wellbeing products in Australia, New Zealand, Mainland China, and South-East Asia.

Trajan Group Holdings

Market Cap: AU$112.1m

Develops, manufactures, and sells analytical and life science products and devices in Malaysia, Japan, Australia, New Zealand, the United States, Europe, the Middle East, Africa, and India.

Island Pharmaceuticals

Market Cap: AU$104.0m

A drug repurposing company, focuses on the development of antiviral therapeutics for antiviral therapeutics in Australia and the United States of America.

Alterity Therapeutics

Market Cap: AU$97.9m

Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.

Actinogen Medical

Market Cap: AU$95.3m

A biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia.

Imugene

Market Cap: AU$88.7m

A clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia.

Amplia Therapeutics

Market Cap: AU$87.2m

A clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia.

Vitrafy Life Sciences

Market Cap: AU$83.0m

Engages in the research, development, and commercialization of cryopreservation solutions in Australia.

Medical Developments International

Market Cap: AU$76.6m

Manufactures and distributes emergency medical solutions in Australia, Asia, Europe, the United States, and internationally.

Radiopharm Theranostics

Market Cap: AU$73.3m

A clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs.

Nyrada

Market Cap: AU$71.7m

A pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Neurizon Therapeutics

Market Cap: AU$66.8m

A clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases.

Tryptamine Therapeutics

Market Cap: AU$59.0m

A clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States.

Genetic Signatures

Market Cap: AU$56.8m

Operates as a molecular diagnostic company in Australia, the Asia Pacific, Europe, the Middle East, Asia, and the Americas.